The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | An update on research into JNJ-90014496 for DLBCL
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, comments on ongoing research into the use of prizloncabtagene autoleucel (prizlon-cel; JNJ-90014496) for diffuse large B-cell lymphoma (DLBCL). This product is a CD19/CD20-targeting autologous CAR T-cell that will be investigated in an upcoming Phase III trial. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
JNJ-4496 is a very exciting CD19, CD20 targeting autologous CAR T-cell. This past summer, we provided updated results from the Phase Ib study. That study continues to enroll more patients, specifically in the relapsed/refractory setting for DLBCL. There are some other cohorts that we’re enrolling in that study. And then also importantly, like we’re seeing with other CD19, CD20 CAR T-cells, a Phase III clinical trial in second-line DLBCL that is planned and will be underway in 2026, where patients are randomized to either CD19, CD20 JNJ-4496 versus standard of care CD19 CAR T-cells in the second-line DLBCL setting...
JNJ-4496 is a very exciting CD19, CD20 targeting autologous CAR T-cell. This past summer, we provided updated results from the Phase Ib study. That study continues to enroll more patients, specifically in the relapsed/refractory setting for DLBCL. There are some other cohorts that we’re enrolling in that study. And then also importantly, like we’re seeing with other CD19, CD20 CAR T-cells, a Phase III clinical trial in second-line DLBCL that is planned and will be underway in 2026, where patients are randomized to either CD19, CD20 JNJ-4496 versus standard of care CD19 CAR T-cells in the second-line DLBCL setting. So that’s going to be a really important study to help us understand if a CD19/20 CAR T-cell is better than a CD19 alone CAR T-cell.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
